CLASS II Drug recall · Reported 3 Sep 2025 · FDA Enforcement Report

Lisdexamfetamine Dimesylate Capsules, 40 mg recalled by Lannett Company

Lannett Company is recalling Lisdexamfetamine Dimesylate Capsules, 40 mg, distributed nationwide in the US. The recall was initiated on 11 Aug 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 25280726A, Exp. Date 03/2027
NDC0527-4661, 0527-4662, 0527-4663, 0527-4664, 0527-4665, 0527-4666
UPC0305274664379, 0305274666373, 0305274661378, 0305274665376, 0305274667370, 0305274663372
Quantity recalled8544 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0599-2025
FDA event ID
97397
Recalling firm
Lannett Company, Seymour, IN
Manufacturer
Lannett Company, Inc.
Classification
Class II
Status
Terminated
Recall initiated
11 Aug 2025
FDA classified
25 Aug 2025
Reported
3 Sep 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects
Drug class
ADHD Medication

Timeline

11 Aug 2025Recall initiated by company
25 Aug 2025Classified by FDA+14 days
3 Sep 2025Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

Lisdexamfetamine Dimesylate Capsules, 40 mg, 100-count bottles, Rx Only, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC 0527-4664-37

Where it was distributed

Nationwide within the USA

Nationwide

Questions about this recall

Is Lisdexamfetamine Dimesylate Capsules, 40 mg recalled?

Yes. Lannett Company recalled Lisdexamfetamine Dimesylate Capsules, 40 mg on 11 Aug 2025. The recall is Class II and its status is Terminated. Recall number D-0599-2025.

Why was it recalled?

Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg.

Which lots are affected?

Lot #: 25280726A, Exp. Date 03/2027

Where was it sold?

Nationwide within the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Lannett Company

All 15
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIDextroamphetamine Saccharate recalled by Lannett CompanyDextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine SulfateLannett CompanyPackaging DefectsNationwide
DrugCLASS IINiacin Extended-release Tablets, USP, 1,000 mg recalledNiacinLannett CompanyPotency & AssayNationwide
DrugCLASS IIIPrimidone Tablets USP, 250mg recalled by Lannett CompanyPrimidoneLannett CompanyOtherNationwide
DrugCLASS IINiacin Extended-release Tablets, USP, 1,000 mg recalledNiacinLannett CompanyPotency & AssayNationwide
DrugCLASS IIDextroamphetamine Saccharate, Amphetamine Aspartate recalledDextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine SulfateLannett CompanyOtherOH

Other Lisdexamfetamine Di recalls

All 11